Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRETCH: Alagebrium in Systolic Hypertension
NCT00302250Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in isolated systolic hypertension (ISH) comparing Alagebrium with Placebo (2 arms). Primary endpoint: Flow-Mediated Vasodilation at 8 weeks. Started Feb 2006; status: completed.
02
Drugs
alagebrium
03
Conditions
isolated systolic hypertension (ISH)
Beyond the preview
Go deeper on NCT00302250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302250.